Protalix Biotherapeutics (NYSEAMERICAN:PLX) has been given a $4.00 price target by HC Wainwright in a report issued on Tuesday. The firm presently has a “buy” rating on the stock.
Separately, Zacks Investment Research lowered Protalix Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th.
NYSEAMERICAN PLX opened at $0.65 on Tuesday. Protalix Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $0.92.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $2.01 million during the quarter, compared to analysts’ expectations of $7.00 million.
A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. SG Americas Securities LLC acquired a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 225,000 shares of the company’s stock, valued at approximately $121,000. SG Americas Securities LLC owned about 0.15% of Protalix Biotherapeutics at the end of the most recent reporting period.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Further Reading: How much money do you need to begin day trading?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.